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The Assay and Properties of Labile
Factor (Factor V)
Armand J. Quick*
Department of Biochemistry, Marquette University School of
Medicine, Milwaukee, Wisconsin
(RECEIVED FOR PUBLICATION SEPTEMBER 9, 1960)
Abstract:
Human oxalated plasma stored at 4°C. until the prothrombin time is
increased beyond 60 sec. is a reliable medium for assaying labile factor
(factor V) because its response to added labile factor corresponds
quantitatively to that of plasma from patients with congenital deficiency of
this factor. Such an agreement is not obtained with plasma stored at 37°C.
The stability of labile factor is closely associated with ionized calcium. The
addition of thrombin to fresh oxalated plasma causes an apparent
hyperactivity of labile factor, but this is completely removed by adsorption
with Ca3(PO)2. Oxalated plasma when adsorbed with Ca3(PO4)2 before
treatment with thrombin does not develop this adventitious activity, nor does
it occur in stored plasma treated with thrombin. The seemingly high labile
factor activity in serum can be explained by the activation of this factor which
is independent of labile factor but acts synergistically with it. The true labile
factor concentration can be determined only after the accelerator is removed
by adsorption with Ca3(PO4)2. A close agreement between the consumption of
prothrombin and the loss of labile factor during clotting is observed.
The discovery in 1943 of a new clotting factor now commonly known as labile
factor or factor V, which was not recognized in the classical theory of blood
coagulation formulated by Morawitz in 1904, initiated a radically new
approach to the study of coagulation mechanisms and the haemorrhagic
diseases. Owren (1947a) described the first case in which a bleeding state
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was caused by lack of a factor which appeared to be similar or identical with
the one which is decreased when oxalated human plasma is stored at 4°C. On
the assumption that the prolonged prothrombin time of such stored plasma is
caused specifically by a loss of labile factor, a method of assay using a stored
human plasma as the medium was developed by Quick and Stefanini (1948).
With this procedure, it was shown that human blood contains a much lower
concentration of labile factor than the blood of the common laboratory
animals. Since there had been no opportunity to compare stored plasma
directly with that from a patient with congenital deficiency of labile factor, the
unequivocal reliability of the assay method could not be established. With the
availability recently of blood from three siblings having strikingly low
concentrations of labile factor, such a comparative study could be made, and
it prompted a reinvestigation of this clotting factor.

Material and Methods
Collection of Blood. — A silicone-coated needle and syringe were used
and the blood was transferred to test-tubes similarly coated. These were kept
in an ice bath until used.

One-stage Prothrombin Time. — The exact procedure as
previously described (Quick, 1957) was followed. This included using sodium
oxalate as the anticoagulant, acetone-dehydrated rabbit brain as the
thromboplastin reagent, and 0.01M CaCl2 for recalcification. A prothrombin
time of 12 sec. for fresh normal human plasma was mandatory in the control
for each experiment.

Adsorption of Plasma to Remove Prothrombin and
Stable Factor (Factor VII). — One millilitre of a suspension of
0.012M Ca3(PO4)2 contains the correct amount of adsorbent to remove
completely the prothrombin and stable factor (factor VII) from 1 ml. of
oxalated rabbit plasma. The required volume of the suspension is pipetted
into a test-tube and the Ca3(PO4)2 is packed by centrifugation. The
supernatant water is poured off, and after the tube is drained the plasma is
added and mixed with the Ca3(PO4)2. After five minutes the adsorbent is
removed by high centrifugation.

Results
Comparison of Stored Human Plasma with Plasma from
Subjects Having Congenital Deficiency of Labile
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Factor.— On adding an equal volume of fresh normal oxalated plasma
either to plasma from a patient with congenital deficiency of labile factor or to
stored plasma, a mixture is obtained which has approximately a normal
prothrombin time (11 -13 sec.) (Table I). No correction is obtained when
labile-factor- deficient plasma is mixed with stored plasma. On adding fixed
amounts of deprothrombinized rabbit plasma, which has a high concentration
of labile factor, to the patient's plasma and to stored plasma, the correction of
the prothrombin time is quantitatively the same in both types of plasma
except that, with increasing amounts, a minimum prothrombin time of 8 sec.
is obtained in stored plasma and 1 1 sec. in the patient's fresh plasma. When
the patient's plasma is stored for 48 hours in glass at 40 C., a minimum
prothrombin time of 8+ sec. is then obtained. A probable explanation for this
will be offered in the discussion.
Table I
Comparison Of Plasma From Patients Having Congenital Labile Factor Deficiency With Stored
Plasma In The Response To Added Labile Factor
Prothrombin Time (sec.)
Patient 1*
Patient 2
Stored Plasma
95
42
53
Undiluted plasma
Plasma diluted with an equal volume of normal
11.5
13
12
plasma
Plasma diluted with an equal volume of stored
95
48
55
plasma
Amount of deprothrombinized rabbit plasma
added to 0-1 ml. plasma:
23
20
23
0.001 ml.
14
15
14
0.005 ml.
11
11.5
12
0.01 ml.
10
12
12
0.02 ml.
8
11.5
11.5
0.05 ml.
8.5†
8.5†
0.05 ml.
* The basic prothrombin consumption time of Patient 1 was 10.5 sec. When 0.1 ml. of
deprothrombinized rabbit plasma was added to 1 ml. of the patient's blood before clotting, the
prothrombin consumption time was 45 sec.
†After 48 hours' storage in glass.

The results in Table I show that normal plasma stored at 4°C. appears to be
nearly identical to plasma from patients with congenital labile factor
deficiency. The ease with which labile factor can be diminished by storage at
4°C. makes the preparation of plasma suitable for assaying labile factor very
simple.
The method of Wolf (1953) for preparing plasma for assaying labile
factor was found unsatisfactory. He incubates oxalated plasma at 37°C. for 24
hours. From the results presented in Table II, it is evident that changes other
than loss of labile factor occur in the plasma, so that the addition of excess
labile factor does not bring the prothrombin time to normal as it will when
added to plasma stored at 4°C.
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Table II
Comparison Of Human Oxalated Plasmas Stored At 4°C. For 14 Days And At 37°C.
For 24 Hours In Response To Added Labile Factor
Prothrombin Time (sec.)
Fresh
Stored at 4°C
Stored at 37°C
for 14 Days
for 24 Hours
Deprothrombinized rabbit plasma added
to 0-1 ml. plasma:
240
60
12
0 ml.
50
10
12
0.01 ml.
18
8
11
0.05 ml.

Assay Method for Labile Factor.— Normal oxalated plasma is
distributed in 5 ml. portions to test-tubes which are placed in a refrigerator
kept at 4°C. The prothrombin time is determined after seven days, and again
at several days' intervals, until it has increased to 60 sec. This requires about
a fortnight. The plasmas are pooled and stored at -20°C.
The labile factor curve is based on the finding that when 1 vol. of fresh
human plasma is mixed with 9 vol. of stored plasma, the mixture has a
prothrombin time which averages about 18 sec. The usual range is 17 to 20
sec. A plasma giving a correction of 18 sec. is arbitrarily designated as having
a labile factor concentration of 100, and, since 1 vol. of this plasma is mixed
with 9 vol. of stored plasma which has a concentration of less than 1%, the
18 sec. can be regarded as the prothrombin time of a plasma containing 10%
of labile factor. By means of varying dilutions of stored plasma with fresh,
values are obtained from which a curve can be constructed correlating the
prothrombin time with labile factor deficiency (Fig. 1). It will be noted that the
prothrombin time becomes 12 sec. when 4 vol. of fresh plasma is mixed with
6 vol. of stored plasma. Fresh plasma contains over twice as much labile
factor as is required to maintain the prothrombin time at 12 sec.;
consequently, over half can be lost before the prothrombin time is prolonged.
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In carrying out the test, the plasma to be assayed is adsorbed with
Ca3(PO4)2 at 40 C. This removes very little labile factor, but it does take out
an accelerator which may be present. One-hundedth of a millilitre of the
adsorbed plasma is mixed with 0.09 ml. of stored human plasma and the
prothrombin time of the mixture determined. The value in terms of
percentage of labile factor is read from the chart and multiplied by 10
because of the dilution.
The assay method is sensitive to small changes in labile factor even in
the range before the prothrombin time is affected. This is illustrated by the
simple experiment of incubating oxalated human plasma for 30 min. at 37°C.
Owren (1947b) states that no deterioration of factor V occurs in this short
period, yet when studied by our method (Table III) it is found that the activity
decreased from 120% to 86%, which is a drop of 28%.

Concentration of Labile Factor in Various Laboratory
Animals.— The determination of labile factor in the blood of the common
laboratory animals is simple because the concentration is much higher than in
human plasma. One need only determine how much the plasma has to be
diluted to correct the prothrombin time of stored human plasma to 18 sec.,
which has been set as the normal correction when 1 vol. of fresh human
plasma is mixed with 9 vol. of stored plasma. In determining the labile factor,
the animal plasma is diluted with saline in various proportions. To 0.09 ml. of
stored plasma, 0.01 ml. of the diluted plasma is added and the prothrombin
time determined. From the prothrombin time obtained, the concentration of
labile factor is calculated. The outstanding finding is the high concentration of
labile factor in rabbit plasma and the low level in human plasma (Table IV).
Table III
Effect Of Incubating Oxalated Plasma At 37°C. On Labile Factor
Prothrombin Time (sec.)
Basic
Mixed with 9
vol. of Aged
Plasma
17
12
Before incubation
19
12
After 30 min. incubation
30
11
After 120 min. incubation

Labile
Factor
(%)
120
86
29

Table IV
Relative Concentration Of Labile Factor(Factor V)
In Plasma Of Various Species
Man Rabbit
Dog
Cat
Cow
Sheep
100
5,000 1,000 350-500
800 300-500
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Table V
Effect Of Various Anticoagulants On Prothrombin Time
And Labile Factor During Storage At 4°C.
Prothrombin Time
Anticoagulant Time of
Storage
In Glass
In Silicone
(hr.)
Basic
Corrected
Mixed
Basic
Corrected
(sec.)
for Labile
with 9
(sec.)
for Labile
Factor *
vol. Aged
Factor *
(sec.)
Plasma†
(sec.)
(sec.)
12
12
17
12
12
Sodium
0
12
16.5
29
8.5
14
oxalate 0.1M
24
12
23
41
8
20
48
11
12
17
12
12
Sodium
0
12
12
18
8
9
citrate 0.1M
24
11
13
20
8.5
10.5
48
12
12
17
12
12
Sodium
0
12
14.5
21
8.5
13
citrate 0.2M
24
12
17.5
25
9
16
48
11
12
None
0
11
12
24
11.5
12
48
* To 0.09 ml. of the plasma, 0.01 ml. of deprothrombinized rabbit plasma was added.
†To 0.09 ml. of aged plasma, 0.01 ml. of the plasma studied was added.

Mixed
with 9
vol. Aged
Plasma†
(sec.)
17
26
36
17
18
17.5
17.5
20.5
24
17
16.5
17

Effect of Anticoagulants on Labile Factor in Plasma
Stored at 4°C.— Three types of plasma were studied: oxalated, citrated,
and native. The results are recorded in Table V. The decrease of labile factor
is greatest in oxalated plasma, but it is also fairly rapid when plasma is mixed
with 0.2M sodium citrate. With 0.1M sodium citrate, the loss of labile factor is
greatly retarded and in native plasma is almost negligible in the first 48
hours. The decrease of labile factor is not significantly different in glass or
silicone-coated containers, but the prothrombin activity as measured by the
prothrombin time after adding an excess of labile factor is increased in glass
but remains practically unchanged in silicone.

Concentration of Labile Factor in Serum.— When human blood
is clotted in glass, the resulting serum appears to have a higher labile factor
activity than does the corresponding oxalated plasma as shown in Table VI.
When the serum is adsorbed with Ca3(PO4)2, this hyperactivity is lost and the
concentration of labile factor is found actually to be low, suggesting that much
of this factor is consumed during clotting. If platelet-poor plasma is clotted,
the resulting serum also shows the apparent hyperactivity, which, after
adsorption, is lost, but the residual concentration of labile factor is higher
than in the serum obtained from the clotting of whole blood or platelet-rich
plasma.

Journal of Clinical Pathology, Vol. 13, No. 6 (November 1960): pg. 457‐462. DOI. This article is © BMJ Publishing Group
and permission has been granted for this version to appear in e‐Publications@Marquette. BMJ Publishing Group does not
grant permission for this article to be further copied/distributed or hosted elsewhere without the express permission
from BMJ Publishing Group.

6

NOT THE PUBLISHED VERSION; this is the author’s final, peer‐reviewed manuscript. The published version may be
accessed by following the link in the citation at the bottom of the page.

Table VI
Labile Factor Activity in Serum
Stored oxalated plasma (ml.)
Serum from normal blood (Serum A)(ml.)
Prothrombin time (sec.)
Stored oxalated plasma (ml.)
Serum A adsorbed with Ca3(PO4)2 (ml.)
Prothrombin time (sec.)
Stored oxalated plasma (ml.)
Serum from platelet-poor plasma (Serum B) (ml.)
Prothrombin time (sec.)
Stored oxalated plasma (ml.)
Serum B adsorbed with Ca3(PO4)2 (ml.)
Prothrombin time (sec.)
Stored oxalated plasma (ml.)
Serum from platelet-rich plasma (Serum C) (ml.)
Prothrombin time (sec.)
Stored oxalated plasma (ml.)
Serum C adsorbed with Ca3(PO4)2 (ml.)
Prothrombin time (sec.)

0.07
0.03
5.5
0.07
0.03
20.0
0.07
0.03
5.2
0.07
0.03
12.0
0.07
0.03
7.5
0.07
0.03
18.0

0.08
0.02
6.5
0.08
0.02
23.0
0.08
0.02
6.5
0.08
0.02
13.0
0.08
0.02
7.5
0.08
0.02
21.0

0.09
0.01
8.0
0.09
0.01
29.0
0.09
0.01
8.0
0.09
0.01
16.0
0.09
0.01
8.2
0.09
0.01
25.0

Action of Thrombin on Labile Factor in Oxalated
Plasma.— When thrombin is added to oxalated plasma, the resulting
defibrinated product has, like serum, a distinct hyperactivity when tested on
stored plasma (Table VII),
Table VII
Effect Of Thrombin On Labile Factor Activity
Stored oxalated plasma (ml.)
0.07 0.08
Fresh oxalated plasma (Plasma A) (ml.)
0.03 0.02
Prothrombin time (sec.)
12.2 13.5
0.07 0.08
Stored oxalated plasma (ml.)
Plasma A treated with thrombin* (Plasma B) (ml.)
0.03 0.02
Prothrombin time (sec.)
9.0 10.0
0.07 0.08
Stored oxalated plasma (ml.)
Plasma B adsorbed with Ca3(PO4)2 (ml.)
0.03 0.02
Prothrombin time (sec.)
15.0 19.0
Stored oxalated plasma (ml.)
0.07 0.08
Plasma A adsorbed with Ca3(PO4)2 (Plasma C) (ml.) 0.03 0.02
Prothrombin time (sec.)
13.0 16.0
Stored oxalated plasma (ml.)
0.07 0.08
0.03 0.02
Plasma C treated with thrombin* (ml.)
Prothrombin time (sec.)
12.5 14.5
Stored oxalated plasma (ml.)
0.07 0.08
Stored plasma treated with thrombin* (ml.)
0.03 0.02
Prothrombin time (sec.)
48.0 47.5
* Five units of thrombin were added to 1 ml. of plasma. The
defibrinated plasma was kept at 4°C. for one hour before testing.

0.09
0.01
17.5
0.09
0.01
11.0
0.09
0.01
22.0
0.09
0.01
18.5
0.09
0.01
17.0
0.09
0.01
44.0
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but adsorption with Ca3(PO4)2 removes this increased activity. When oxalated
plasma is adsorbed with Ca3(PO4)2 before the addition of thrombin, no
adventitious activity develops : likewise, in stored oxalated plasma, this
activity fails to develop on treatment with thrombin.

Discussion
The observation of various investigators that in congenital deficiency of
labile factor the other plasma constituents which influence the prothrombin
time are normal suggests that the plasma from such patients should be ideal
for assaying the factor. It has, however, the disadvantage of not being readily
available. The finding that normal plasma stored at 4°C. can be reliably
substituted makes the quantitative study of labile factor possible and easy for
any clinical laboratory.
The concentration of labile factor in human blood is much lower than in
the common laboratory animals. This observation, which was made in the
original study (Quick, 1943), has been confirmed by Murphy and Seegers
(1948) and by Didisheim, Hattori, and Lewis (1959). The suggestion of
Murphy and Seegers that the low level in man may "offer at least a partial
explanation for the reported discrepancy of prothrombin values obtained by
the one-stage and two-stage methods" is not supported experimentally. The
concentration of labile factor in normal human plasma is not the limiting
factor that fixes the prothrombin time (Quick, 1958). Over one-half of the
labile factor must be lost before the prothrombin time becomes prolonged as
is shown in this study and was earlier reported by Alexander and DeVries
(1949).
Confusion still exists concerning the stability and alteration of activity
of labile factor. It was originally observed (Quick, 1943) that native chicken
and goose plasma showed no increase of prothrombin time kept seven days
in a refrigerator. When these plasmas were oxalated, the prothrombin time
became markedly prolonged on storage. This suggests that the stability of
labile factor is decreased in the absence of ionized calcium. In the present
study it is shown that native human plasma loses little labile factor on storage
in 48 hours, whereas the oxalated plasma does. Significantly, when 9 vol. of
plasma is mixed with 1 vol. of 0.1M sodium citrate, the resulting mixture
exhibits no increase in the prothrombin time; it actually shows a decrease. If,
instead, 0.2M citrate is used, the same increase in prothrombin time is
observed as in oxalated plasma. The difference in stability of labile factor in
citrated and oxalated plasma was observed by Fahey, Ware, and Seegers
(1948), but they offered no explanation. Since 0.1M sodium citrate does not
completely depress the ionized calcium, it seems justifiable to conclude that
the greater stability of the labile factor in the weaker citrate plasma is due to
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ionized calcium which is not completely depressed (Hussey, Quick, Stefanini,
Consolazio, and Sargent, 1950).
When blood citrated with 0.1M citrate is stored in glass at 4°C., the
prothrombin time decreases from the initial 12 sec. to about 9 sec., whereas
no change occurs when stored in silicone. It is further observed that both the
oxalated and citrated plasmas stored in glass have prothrombin times of 8 to
9 sec. when excess labile factor is added, but the same plasmas kept in
silicone-coated test-tubes retain a prothrombin time of approximately 12 sec.
Alexander and DeVries also noted this enhanced prothrombin activity on
storage in glass and remarked that it could not be explained. Shortly before
this, Quick and Stefanini (1949) formulated the hypothesis that the
prothrombin in human blood is only partly free and that a large fraction is in
an inactive state. On storage in glass the inactive prothrombin becomes
activated, whereupon the prothrombin time is shortened. In both oxalated
and citrated plasma this activation readily occurs in glass but not in silicone.
Since the rate at which labile factor decreases in oxalated and in 0.2M sodium
citrated plasmas is much greater than the speed of activation of
prothrombinogen, the prothrombin time steadily increases. In the plasma
with 0.1M sodium citrate, the reverse is true because the rate with which
labile factor disappears is much slower than that of the activation of inactive
prothrombin.
During storage of adult human plasma in glass at 4°C., two changes
are occurring simultaneously: labile factor is diminishing and, according to the
author's hypothesis, inactive prothrombin is being converted to the active
form. The latter reaction, which is measurable by the one-stage prothrombin
time, is masked unless the first is retarded, as occurs when plasma is mixed
with 0.1M sodium citrate. These changes occur in the absence of thrombin.
When oxalated plasma is treated with thrombin and incubated for one hour to
permit inactivation of the added thrombin, the resulting defibrinated plasma
has, when tested by our assay method, shown a marked increase in what
appears to be labile factor activity. When, however, the defibrinated plasma is
treated with Ca3(PO4)2, this hyperactivity is lost and the adsorbed plasma is
found to have a slightly lower concentration of labile factor than it had before
treatment with thrombin. This clearly suggests that thrombin brings about the
generation of another factor which acts synergistically with labile factor to
shorten the prothrombin time markedly. If oxalated plasma is adsorbed with
Ca3(PO4)2 before treatment with thrombin, no hyperactivity develops.
Likewise, thrombin fails to produce this adventitious activity in stored plasma.
This factor which is activated by thrombin appears to be distinct and
independent of labile factor. It is adsorbed by Ca3(PO4)2and is absent in
stored plasma. It is probably identical with the agent Alexander, DeVries,
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Goldstein, and Landwehr (1949) named S.P.C.A. (serum prothrombin
conversion accelerator).
The activation of this new factor explains the apparently high labile
factor activity in serum. When, however, the serum is adsorbed with
Ca3(PO4)2, it is found that the labile factor has actually diminished. The more
complete the clotting as measured by the prothrombin consumption test, the
greater the decrease of labile factor, and conversely in defective clotting, such
as occurs in haemophilia and thrombocytopenia, much labile factor remains in
the serum. This was reported by Alexander, Goldstein, and Landwehr (1950)
and again recently by Douglas (1956).
These observations suggest that labile factor enters the reaction as a
reactant and not as an accelerator. At the time Fahey et al. (1948) carried out
their studies on the factor which they called Ac-globulin, the S.P.C.A. of
Alexander had not been recognized. The observation of greater activity in
serum was regarded as an activation of Ac-globulin; they distinguished
between plasma Ac-globulin and serum Ac-globulin and postulated that the
factor existed in plasma in an inactive state, probably as a proenzyme. Owren
(1951) has also accepted the view that the factor is in a precursor state and
has designated it proaccelerin. As Alexander et al. (1950) pointed out, the
activity which is called serum Ac-globulin (and one can also include Owren's
accelerin) is in all probability a mixture of plasma Ac-globulin or labile factor
with S.P.C.A. The hypothesis that labile factor exists in blood in a precursor
state and that when activated it becomes an accelerator is based on
experimental observations which require reinterpretation.
The probable place at which labile factor enters the coagulation
reaction was investigated by Quick and Stefanini (1950). They observed that
little or no prothrombin consumption occurs when tissue thromboplastin
(rabbit brain extract) is added to recalcified stored plasma, but that the
addition of increasing amounts of labile factor to this system brought about
corresponding increments of prothrombin consumption. This indicated that
labile factor acts stoichiometrically and is essential in the utilization of
extrinsic thromboplastin. Our observation that prothrombin consumption is
very low in a patient with congenital deficiency of labile factor shows that the
factor is also essential for the utilization of intrinsic thromboplastin. It can be
concluded that labile factor enters at a late stage of the clotting reaction. It
actually appears to be a thromboplastin co-factor, a term which Honorato
(1947) suggested. Douglas (1956) has also concluded that the factor enters
at a stage later than antihaemophilic globulin, Christmas factor, and platelets.
This study was made possible through the kind co-operation of Dr.
Irving Friedman, Hektoen Institute, Cook County Hospital, Chicago, Illinois. I
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wish to thank him for the opportunity of studying his patients with severe
labile factor deficiency.
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